Report
Maria Vara

Medartis: Solid finish to 2024 with numerous strategic plans for 2025

Medartis reported FY2024 core sales growth of 11.7% (CER), placing it at the lower end of its updated guidance range of 12–15% post-H1, with total sales reaching CHF224.8mm (CHF219.6m core). Profitability outperformed expectations, delivering a 19.0% core EBITDA margin—up 1.9PP YoY versus guidance
Underlying
Medartis AG

Medartis Holding AG is a Switzerland-based holding company of the Medartis Group, which is engaged in manufacturing medical devices and implants. The Group develops, manufactures and distributes to surgeons, hospitals and medical centers titanium screws, plates, surgical instruments and system solutions for internal fracture fixation. Medartis AG, the Company's wholly-owned subsidiary, has developed such technologies as TriLock for locking the screw into the plate, SpeedTip, a screw that does not require pre-drilling, and HexaDrive self-holding screw and screw-driver. It has two product lines. The APTUS product line comprises upper and lower extremities products for hand, wrist, elbow, shoulder and foot fixation. The MODUS line combines products dedicated to cranio-maxillofacial (CMF) surgery. The Group's products are sold globally in more than 30 countries, including Germany and the United States, either directly through its sales subsidiaries, or through third-party distributors.

Provider
Bryan Garnier
Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

Analysts
Maria Vara

Other Reports on these Companies
Other Reports from Bryan Garnier

ResearchPool Subscriptions

Get the most out of your insights

Get in touch